NCT04407442View on ClinicalTrials.gov

Daratumumab, Azacitidine, and Dexamethasone for Treatment of Patients With Recurrent or Refractory Multiple Myeloma Previously Treated With Daratumumab

PHASE2TerminatedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

November 30, 2020

Primary Completion Date

April 30, 2023

Study Completion Date

April 30, 2023

Conditions
Recurrent Plasma Cell MyelomaRefractory Plasma Cell Myeloma
Interventions
DRUG

Azacitidine

Given IV

BIOLOGICAL

Daratumumab

Given SC

DRUG

Dexamethasone

Given IV or PO

Trial Locations (1)

94143

University of California, San Francisco, San Francisco

Sponsors

Collaborators (1)

Janssen Pharmaceuticals
All Listed Sponsors
collaborator

Janssen Pharmaceuticals

INDUSTRY

collaborator

Multiple Myeloma Research Foundation

OTHER

lead

University of California, San Francisco

OTHER